A randomized controlled study of efficacy of topical non-steroidal anti- inflammatory cream in treating mild to moderate seborrheic dermatitis in Thai population

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20230811003

Enrollment

Registered

2023-08-11

Start date

2023-06-26

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patient with mild to moderate seborrheic dermatitis Seborrheic dermatitis, Avenanthramides, Piroctone olamine, Acetamide MEA, Biosaccharide Gum-2, Zinc PCA, Nutradeica DS, Hydrophilic cream

Interventions

The skincare formulation combines Piroctone Olamine, Stearyl Glycyrrhetinate, Biosaccharide Gum - 2, Dihydroavenanthramide, Zinc PCA and Acetamide MEA,The skincare formulation includes Cetyl alcohol,

Active Comparator Other,Active Comparator Other

Non-steroidal anti-inflammatory cream (Nutradeica),Hydrophilic cream

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Healthy patients with mild to moderate seborrheic dermatitis

Exclusion criteria

Exclusion criteria: 1. Other active skin diseases that may interfere with the assessment of seborrheic dermatitis severity. 2. History of using topical and oral anti-inflammatory medication within the 4 weeks prior. 3. History of allergy to any component of the product. 4. Pregnancy or breastfeeding.

Design outcomes

Primary

Measure	Time frame
Seborrheic dermatitis severity baseline, 4 weeks, 8 weeks, 12 weeks Modified seborrheic dermatitis area severity index (mSDASI),Investigator Global Assessment 4 weeks, 8 weeks, 12 weeks 5-point ordinal scale (worsening, no response, mild response, good response, excellent response)	—

Secondary

Measure	Time frame
Skin hydration baseline, 4 weeks, 8 weeks, 12 weeks Corneometer,Trans-epidermal water loss baseline, 4 weeks, 8 weeks, 12 weeks Tewameter,Skin sebum baseline, 4 weeks, 8 weeks, 12 weeks Sebumeter,Erythema baseline, 4 weeks, 8 weeks, 12 weeks Colorimeter,Frequency of 0.02% Triamcinolone acetate use within 12 weeks Times and duration of treatment,Patient satisfaction at 12 weeks Patient Satisfaction Scale 0-10,Patient Global Assessment 4 weeks, 8 weeks, 12 weeks 5-point ordinal scale (worsening, no response, mild response, good response, excellent response)	—

Measure

Time frame

Skin hydration baseline, 4 weeks, 8 weeks, 12 weeks Corneometer,Trans-epidermal water loss baseline, 4 weeks, 8 weeks, 12 weeks Tewameter,Skin sebum baseline, 4 weeks, 8 weeks, 12 weeks Sebumeter,Erythema baseline, 4 weeks, 8 weeks, 12 weeks Colorimeter,Frequency of 0.02% Triamcinolone acetate use within 12 weeks Times and duration of treatment,Patient satisfaction at 12 weeks Patient Satisfaction Scale 0-10,Patient Global Assessment 4 weeks, 8 weeks, 12 weeks 5-point ordinal scale (worsening, no response, mild response, good response, excellent response)

—

Countries

Thailand

Contacts

Public ContactChanat Kumtornrut

Faculty of Medicine, Chulalongkorn University

chanat_1@yahoo.com66814595965

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026